Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan
This study presents practical information on outcomes and treatment patterns of RDV in immunocompromised inpatients diagnosed with COVID-19.
Authors
- Manami Yoshida (ORCID: https://orcid.org/0000-0002-4454-4654)
- Mazin Abdelghany (ORCID: https://orcid.org/0000-0001-5192-8659)
- Yi Piao (ORCID: https://orcid.org/0009-0008-3162-543X)
- Nao Taguchi
- Rikisha Gupta (ORCID: https://orcid.org/0000-0001-9784-416X)
- Hiroshi Yotsuyanagi (ORCID: https://orcid.org/0000-0001-7882-5262)
- Mel Chiang
- Mark Berry (ORCID: https://orcid.org/0000-0002-8534-2012)
- Jami Peters
- Chenyu Wang (ORCID: https://orcid.org/0000-0002-3675-3616)
Institutions
- YKK (Japan) (JP)
- Gilead Sciences (United States) (US)
- KDDI (Japan) (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Journal of Infection and Chemotherapy
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1016/j.jiac.2024.12.007
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences